Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 8/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.35 |
| ▸ | DPP4 | P27487 | 5/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385022 | 1.00 | GAA (0.36) | GAAHPGDDPP7CA12CA1 | |
| SCHEMBL30443171 | 0.98 | CHRM2 (0.37) | GAAHPGDDPP7CA12CA1 | |
| SCHEMBL21773024 | 0.93 | — | — | |
| SCHEMBL19408961 | 0.93 | — | — | |
| SCHEMBL3488662 | 0.93 | — | — | |
| Glycine SCHEMBL4955985 | 0.90 | DPP4 (0.39) | DPP7CHRM2CHRM4CHRM5CHRM1 | |
| Alanine SCHEMBL4955495 | 0.87 | DPP4 (0.44) | DPP7CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL21296547 | 0.83 | — | — | |
| Serine SCHEMBL4955395 | 0.83 | DPP7 (0.40) | DPP7CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4002060 | 0.82 | GAA (0.36) | GAAHPGDDPP7CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018103058-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | WO | disclosed |
| US-20090093454-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093454-A1 | Chemical Compounds | SLC10A1, CYP11B2, CYP4F3 | GAA 466/4885HPGD 419/4885DPP7 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.